Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled...

Area of Science:

• Infectious Diseases
• Virology
• Clinical Pharmacology

Background:

• Oral antivirals are crucial for preventing coronavirus disease 2019 (COVID-19) progression, especially for those vulnerable despite vaccination.
• Favipiravir is widely used for COVID-19 treatment based on perceived efficacy, but large randomized controlled trial (RCT) evidence is limited.
• The study addresses the need for robust clinical data on favipiravir's effectiveness in early COVID-19.

Purpose of the Study:

• To evaluate the efficacy of favipiravir compared to placebo in adults with early mild-to-moderate COVID-19.
• To assess the impact of favipiravir on time to sustained clinical recovery (TT-SCR), COVID-19 progression, and viral shedding.
• To determine if favipiravir offers a clinical benefit over placebo in this patient population.

Main Methods:

• A multicenter, double-blinded, placebo-controlled randomized controlled trial (RCT) involving 1187 adult patients.
• Patients were randomized 1:1 to receive either favipiravir or a placebo.
• Key outcomes included TT-SCR, COVID-19 progression, and time to undetectable SARS-CoV-2 viral shedding.

Main Results:

• No significant difference was observed between favipiravir and placebo groups for TT-SCR (median 7 days, P = .80).
• COVID-19 progression rates were similar (1.9% vs 1.8%, P = .96), as was the time to undetectable virus.
• Favipiravir was well-tolerated, with the most frequent adverse event being elevated uric acid (19.9% vs 2.8%).

Conclusions:

• Favipiravir demonstrated a lack of efficacy in improving time to sustained clinical recovery or preventing progression to severe COVID-19.
• The study concludes that favipiravir should not be used for treating patients with COVID-19.
• Results were consistent across subgroups, reinforcing the lack of therapeutic benefit.